BTK and rheumatoid arthritis: BMS-986142 in particular is an interesting new lead compound that is able to block BTK in reversible manner, with an IC50 value of 0.50 nM; in addition, it shows significant improvements in potency and selectivity compared to BMS-935177, and it is currently in a phase II clinical study for the treatment of RA and Sjögren Syndrome [53,54,55,56,57].